On May 27, 2010
Icahn Emerges From His Corner in Genzyme Fight, But Lacks a Killer Blow
Billionaire activist investor Carl Icahn makes a good case in his battle to install new directors on Genzyme (GENZ)’s board, but his argument is weakest on the one point where it needs to be strongest: The future of Campath.
…
0 Comments